The Vietnamese government recently approved phase 3 clinical trials for SK Bioscience's COVID-19 vaccine candidate GBP510.
|Vietnam has just approved phase 3 clinical studies for SK Bioscience's COVID-19 vaccine candidate GBP510 |
The International Vaccine Institute (IVI), which is working on the COVDI-19 vaccine alongside SK Bioscience, recently received approval to conduct a phase 3 clinical trial in Vietnam for GBP510. The two plan to accelerate development in global studies through five countries including Vietnam, New Zealand, Ukraine, the Philippines, and Thailand.
GBP510 is a COVID-19 vaccine candidate developed by SK Bioscience and the University of Washington's Institute for Protein Design (IPD). In late August, the company began delivering the vaccine candidate in South Korea. The therapeutic candidate was created utilising genetic recombination techniques. It works by injecting the COVID-19 virus's surface antigen protein into the human body, which triggers an immunological response, according to a report by Korea Biomed.
In early 2022, SK Bioscience hopes to acquire phase 3 trial results and apply for emergency use authorisation from countries including Vietnam.
Indeed, South Korean pharmaceutical firms are gearing up their efforts to develop COVID-19 vaccines. In particular, South Korean pharmaceutical firm HLB has signed an MoU with Nanogen, producer of Vietnam's Nanocovax COVID-19 vaccine, to acquire the rights to distribute the vaccine worldwide, except in Vietnam and India, when the vaccine is approved for use.
Last month, South Korea announced to provide over one million COVID-19 vaccine jabs to Vietnam, as the two countries work to strengthen their strategic partnership. This is South Korea's first direct commitment of COVID-19 vaccine donation to a foreign country.